As a point of comparison Cyclopharm is an Aussie company expanding into the US with a product for diagnostic imaging and an existing market in ROW. Half year results showed revenue around $13.3 million and a loss after tax of $7.5 million. Sales in the US are struggling to get rolling whilst waiting on VAC approvals but should grow rapidly although total market I believe would be much smaller than MIGS. Current market cap for the company is around $150 million or about 3 times that of Eye. I think that suggests some upside potential for Nova.
As a point of comparison Cyclopharm is an Aussie company...
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
-0.010(5.26%) |
Mkt cap ! $41.23M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.0¢ | $17.13K | 91.57K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 80630 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 37705 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |